On November 23, 2021, Theralink Technologies, Inc. (the "Company") reported that entered into a Securities Purchase Agreement (the "SPA") with an investor (the "Investor") pursuant to which the Investor agreed to purchase convertible notes ("Notes") and an accompanying warrant ("Warrant") for an aggregate investment amount of $1,000,000.00 (Filing, 8-K, Oncbiomune, NOV 23, 2021, View Source [SID1234596228]). The SPA contains customary representations, warranties, and covenants of the Company and Investor as detailed therein.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Notes have an aggregate face value of $1,000,000 and each Note bears interest at a rate of 8% per annum (which shall increase to 10% per year upon the occurrence of an "Event of Default" (as defined in the Notes)) and shall mature on November 1, 2026 (the "Maturity Date"). The Notes will be funded in three tranches on November 23, 2021, December 1, 2021 and December 31, 2021. The Notes are convertible into shares of the Company’s common stock at a conversion price equal to $0.00366 per share for any amount of principal and accrued interest remaining outstanding (subject to adjustment as provided therein). The Company may prepay the Notes at any time in an amount equal to 110% of outstanding principal balance and accrued interest.

In connection with the Notes, the Investor was issued a Warrant to purchase an amount of common stock equal to 20% of the shares of common stock issuable upon conversion of the Notes at an exercise price of $0.00366 per share (subject to adjustment as provided therein) until November 1, 2026. The Warrants are exercisable for cash at any time.

The foregoing description of the SPA, the Notes, and the Warrant does not purport to be complete, and is qualified in its entirety by reference to Exhibits 4.1, 4.2, and 10.1 hereto, which are incorporated by reference herein.

On November 23, 2021 CureLab Oncology reported that it has been granted a patent protection in India for anti-cancer application of our lead product, Elenagen (Press release, CureLab Oncology, NOV 23, 2021, View Source [SID1234596166]). This brings the total number of countries in which CureLab Oncology has patent protection to over 20 — you can see the complete list here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Because of its huge population and established biotech expertise, we see enormous potential in the Indian market for CureLab’s therapies. According to INVEST INDIA, India is among the top 12 destinations for biotechnology in the world, with an approximately 3% share of the global biotechnology industry. In aggregate, the biotech sector is a key contributor to India’s vision of reaching a $5 trillion economy by 2024.

The rising incidence of cancer in India is expected to boost the immuno-oncology drugs market expansion across the country. According to the Indian Council of Medical Research (ICMR) – National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

The India immuno-oncology drugs market was valued at $172.8 million in 2018 and is expected to experience a CAGR of 13.1% from 2018 through 2026.
Like any promising biotech company, we view a comprehensive, global approach to IP protection as immensely important to our strategic business plan. One reason is that annual industrial biopharmaceutical R&D spending has declined over the past decade, with large pharmaceuticals instead focusing on partnership and acquisition strategies with biotech startups whose technology shows great promise.

As we expand our patent portfolio and geographic operations, we will adapt our IP strategy to maximize the value of the company.

On November 23, 2021 Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) reported that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November 30, 2021 at 12:10 p.m. Eastern Time (Press release, Kiniksa Pharmaceuticals, NOV 23, 2021, View Source [SID1234596035]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

On November 23, 2021 Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, reported that Daniel Vitt, Ph.D., Chief Executive Officer and President, will participate in a fireside chat at the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference, taking place November 29-December 2, 2021 (Press release, Immunic, NOV 23, 2021, View Source;co-33rd-annual-virtual-healthcare-conference-301430529.html [SID1234596006]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation is available for registered attendees via the Piper Sandler conference site from Monday, November 22 to Thursday, December 2 and on the "Events and Presentations" section of Immunic’s website at: View Source An archived replay will be available on the company’s website for a period of 90 days after the conference.

On November 23, 2021 Bionomics Limited (ASX:BNO,OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, reported the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") in relation to a proposed public offering (the "Offering") of American Depositary Shares (ADSs), each of which will represent one or a number of the Company’s ordinary shares in the United States (Press release, Bionomics, NOV 23, 2021, View Source [SID1234596005]). Concurrent with the proposed public offering, Bionomics also intends to list the ADSs on the Nasdaq Stock Market (Nasdaq).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All securities to be sold in the Offering will be offered by Bionomics. The number of securities to be sold and the price per ADS under any proposed Offering have not yet been determined.

Bionomics has applied to list its ADSs on Nasdaq under the ticker symbol "BNOX". The ordinary shares are listed, and upon the completion of the Offering, will continue to trade on the Australian Securities Exchange (ASX) under the symbol "BNO".

A registration statement relating to the securities referred to herein has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.